Iovance Biotherapeutics, Inc. · NASDAQ:IOVA
Iovance Biotherapeutics — Technical Presentation (2023)
7 slides from Iovance Biotherapeutics's technical presentation, 2023
Slide 1: Multicenter Phase II Trial Of LN-145 TIL Cell Therapy Plus Pembrolizumab in ICI-Naïve Metastatic NSCLC
Multicenter Phase II Trial Of LN-145 TIL Cell Therapy Plus Pembrolizumab in Patients With ICI-Naïve Metastatic NSCLC Adam Schoenfeld1; Kai He2; Jason Chesney3; Edward Garon4; Jorge Nieva5; Adrian Sacher6; Sylvia Lee7; Friedrich Graf Finckenstein8; Rana Fiaz8; Melissa Catlett8; Guang Chen8; Viktoria
Slide 2: IOV-COM-202 3A: LN-145 + anti–PD-1 in ICI-naïve mNSCLC
IOV-COM-202 3A: LN-145 + anti–PD-1 in ICI-naïve mNSCLC Merging Potent Immunotherapy Modalities Introduction Methods and Objective • Benefit from front-line ICI ± chemotherapy in patients with • IOV-COM-202 (NCT03645928) is a global, phase 2, multicenter, multicohort mNSCLC is limited by primary and
Slide 3: Results: Baseline Demographics and Safety Data
Results: Baseline Demographics and Safety Data Majority of Patients Were PD-L1–Negative With High Disease Burden Table 1. Baseline Patient and Disease Characteristics Table 2. Non-hematologic TEAEs in ≥30% of Patientsj Table 3. Grade 3/4 Hematologic Lab Characteristics Cohort 3A (N=19) Cohort 3A (N=
Slide 4: Clinical Efficacy: Responses Observed Independent of PD-L1 Status
Results: Clinical Efficacy in ICI-naïve mNSCLC Responses (RECIST v1.1) Observed Independent of PD-L1 Status Figure 2. Best Percentage Change from Baseline in Target Lesion SOD for Evaluable Patients Table 4. Best Overall Response 100 Best Overall Cohort 3A (N=19) Treatment-naïve Post-chemotherapy EG
Slide 5: Clinical Efficacy: Durable Responses Were Observed
Results: Clinical Efficacy in ICI-naïve mNSCLC Durable Responses Were Observed Figure 3. Time to Response, Duration of Response, and Time on Efficacy Assessment for Confirmed Figure 4. Percentage Change from Baseline in Target Lesion SOD Responders (PR or Better) 80 PD-L1 BOR on 3A-03 (PD) Subgroup
Slide 6: Infused TCR Clonotypes Over Time and Cell Dose
Infused TCR Clonotypes Over Time and Cell Dose Infused TIL Persist in Peripheral Blood and Cell Dose Did Not Differ By Response Figure 5. Persistence of Infused TIL* Figure 6. Total Cell Dose 60 p = 0.62 Responder % TCR Repertoire Total Dose (billion) 100 Nonresponder 40 50 20 0 Pre-Infusion Day 4 D
Slide 7: Trial Conclusions
Trial Conclusions TIL Cell Therapy Activity May Be Independent of PD-L1 Status in ICI-naïve mNSCLC • In patients with ICI-naïve mNSCLC, activity of LN-145 plus pembrolizumab was greater than what has previously been reported for LN-145 monotherapy or pembrolizumab alone and was not limited by PD-L1
Iovance Biotherapeutics — Technical Presentation (2023) on 6ix